Cynata Therapeutics Limited (CYYNF) Discusses Imminent Clinical Trial Readouts and Key Milestones in Osteoarthritis and Graft-versus-Host Disease Transcript

SA Transcripts158.08K FollowersFollow5ShareSaveComments Cynata Therapeutics Limited (CYYNF) Discusses Imminent Clinical Trial Readouts and Key Milestones in Osteoarthritis and Graft-versus-Host Disease February 3, 2026 7:30 PM EST Company Participants Kilian Kelly - MD, CEO & DirectorMathias Kroll - Chief Business Officer Conference Call Participants Lauren Nowak Presentation Lauren Nowak So good morning, and thank you for joining Cynata Therapeutics Investor Webinar for the December 2025 quarter. Presenting this morning will be CEO and Managing Director, Dr. Kilian Kelly, who will provide an update on our clinical programs, corporate developments and financial position, followed by a Q&A session. [Operator Instructions] Both Kilian and Chief Business Officer, Dr. Mathias Kroll, will be available to answer your questions. As a reminder, this webinar is being recorded and will be available on the company website in coming days. I'll now hand over to Kilian to formally welcome you all and commence the presentation. Kilian KellyMD, CEO & Director Thanks very much, Lauren, and good morning, everybody, and thank you for joining us today. So as usual, with these quarterly webinars, we'll keep the presentation fairly brief, so we do have time for questions and answers. And the content is fairly high level, focusing on updates from the recently completed quarter. If you are new to the company and perhaps you don't have all of the background, please do have a look at our website where there is a lot of other information that will help you get up to speed. And of course, feel free to reach out if you need to know more. So the big news, of course, as anybody who's been following us will know is that we really are very close now to 2 major clinical trial efficacy readouts. We're expecting 2 different clinical trial results to read out during quarter 2 this calendar